Faculty Opinions recommendation of Palivizumab, a Humanized Respiratory Syncytial Virus Monoclonal Antibody, Reduces Hospitalization From Respiratory Syncytial Virus Infection in High-risk Infants.

Author(s):  
Patrick C Wilson
Sign in / Sign up

Export Citation Format

Share Document